ArticleImmunity, inflammation and disease2026
Identification of Molecular Subtypes for Hepatocellular Carcinoma Based on Ubiquitin-Conjugating Enzyme E2 (UBE2)-Related Genes to Assess Prognosis and Immune Landscape.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of Molecular Subtypes for Hepatocellular Carcinoma Based on Ubiquitin-Conjugating Enzyme E2 (UBE2)-Related Genes to Assess Prognosis and Immune Landscape.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a prevalent and highly aggressive cancer, characterized by elevated morbidity and mortality. Ubiquitin-conjugating enzyme E2 (UBE2) plays a crucial role in regulating HCC development, although the underlying mechanisms remain poorly understood.
methodsHCC patient transcriptomic and clinical datasets were sourced from The Cancer Genome Atlas database. Patients were classified into two distinct subtypes using the K-means clustering method. Prognostic genes were identified through univariate and multivariate Cox regression, as well as least absolute shrinkage and selection operator regression. A nomogram was developed to predict patient prognosis, which was subsequently validated using the independent GEO dataset, GSE14520. Extensive model validation was performed to assess its prognostic significance. Immune landscape characterization was conducted using Single Sample Gene Set Enrichment Analysis (ssGSEA), ESTIMATE, and CIBERSORT algorithms. Drug sensitivity was also evaluated to identify potential therapeutic options.
resultsBased on the expression profiles of 12 UBE2-associated genes, we classified patients into two subtypes and identified six UBE2-related genes as prognostic biomarkers. The risk score effectively predicted patient outcomes, with high-risk individuals showing reduced survival and the low-risk group characterized by elevated immune cell infiltration and unique immune checkpoint expression patterns. Additionally, potential drugs were identified, and drug sensitivity for HCC was evaluated.
conclusionIn this study, we established a prognostic risk model for HCC with strong predictive performance. Risk-based stratification revealed its associations with immune infiltration, immunotherapy response, and drug sensitivity. These findings offer new insights into survival prediction and clinical features in patients with HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.